Brookline Capital Management Comments on CADL Q2 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Equities researchers at Brookline Capital Management issued their Q2 2025 earnings per share (EPS) estimates for Candel Therapeutics in a note issued to investors on Wednesday, July 9th. Brookline Capital Management analyst K. Dolliver forecasts that the company will earn ($0.18) per share for the quarter. Brookline Capital Management has a "Strong-Buy" rating on the stock. The consensus estimate for Candel Therapeutics' current full-year earnings is ($1.47) per share. Brookline Capital Management also issued estimates for Candel Therapeutics' Q3 2025 earnings at ($0.21) EPS and Q4 2025 earnings at ($0.23) EPS.

Candel Therapeutics (NASDAQ:CADL - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported $0.13 EPS for the quarter, beating analysts' consensus estimates of ($0.24) by $0.37.

Other analysts have also issued research reports about the company. Wall Street Zen raised Candel Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright raised Candel Therapeutics to a "buy" rating and set a $23.00 target price on the stock in a research report on Monday, June 30th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Candel Therapeutics has a consensus rating of "Buy" and a consensus price target of $22.00.

Candel Therapeutics Trading Up 1.0%

CADL traded up $0.07 during trading hours on Monday, reaching $6.92. The company's stock had a trading volume of 1,284,147 shares, compared to its average volume of 1,510,180. Candel Therapeutics has a fifty-two week low of $3.79 and a fifty-two week high of $14.60. The stock has a market cap of $346.69 million, a PE ratio of -5.16 and a beta of -0.91. The business's 50-day moving average is $5.45 and its 200-day moving average is $6.55. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.64 and a quick ratio of 4.64.

Institutional Trading of Candel Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC raised its position in Candel Therapeutics by 86.6% in the fourth quarter. Squarepoint Ops LLC now owns 19,311 shares of the company's stock valued at $168,000 after purchasing an additional 8,962 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Candel Therapeutics by 11.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 52,190 shares of the company's stock worth $453,000 after acquiring an additional 5,413 shares during the period. Janney Montgomery Scott LLC increased its position in shares of Candel Therapeutics by 104.3% during the first quarter. Janney Montgomery Scott LLC now owns 21,090 shares of the company's stock worth $119,000 after acquiring an additional 10,765 shares during the period. LPL Financial LLC purchased a new stake in shares of Candel Therapeutics during the fourth quarter worth $93,000. Finally, Northern Trust Corp increased its position in shares of Candel Therapeutics by 3.9% during the fourth quarter. Northern Trust Corp now owns 165,021 shares of the company's stock worth $1,432,000 after acquiring an additional 6,250 shares during the period. Hedge funds and other institutional investors own 13.93% of the company's stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.